Abstract
The Parma group study, a randomized multicenter trial of treatment for patients with chemotherapy-responsive, relapsed aggressive non-Hodgkin’s lymphoma, has established the superiority of high-dose chemotherapy and autologous stem cell transplant over conventional salvage chemotherapy [1]. Subsequently, autologous stem cell transplant has become a standard approach for relapsed non-Hodgkin’s lymphoma. Recent reports also have revealed that high-dose chemotherapy followed by autologous stem cell transplant is superior to standard chemotherapy as a primary treatment for newly diagnosed patients with aggressive non-Hodgkin’s lymphoma [2, 3]. In our institution and the affiliated hospitals, the so-called Fukuoka Blood and Marrow Transplantation Group (upfront high-dose chemotherapy with autologous peripheral blood stem cell transplant after six cycles of the standard CHOP regimen) has been provided as consolidation for newly diagnosed patients as well as relapsed patients with aggressive non-Hodgkin’s lymphoma since 1990 [4]. The specific disease entities that we consider are aggressive B-cell lymphomas, such as diffuse, large B-cell lymphoma and peripheral T-cell lymphomas, at the stage of high intermediate to high risk, according to the International Prognostic Index. The conditioning regimen consists of MCEC (ranimustine 200 mg/m2 × 2, carboplatin 300 mg/m2 × 4, etoposide 500 mg/m2 × 3, cyclophosphamide 50 mg/kg × 2). In total, 3.6 % of patients died of transplant-related causes. The estimated overall survival at 5 years following autologous stem cell transplant was 63 % in aggressive B-cell lymphomas (n = 252) and 62 % in peripheral T-cell lymphomas (n = 39) in the Fukuoka Blood and Marrow Transplantation Group experience. Five-year overall survival was significantly higher in patients transplanted at the first complete remission than in those with other disease status (79 % vs. 50 % in diffuse, large B-cell lymphoma and 83 % vs. 49 % in peripheral T-cell lymphomas, respectively).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.
Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol. 2004;15:283–90.
Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–95.
Kamezaki K, Kikushige Y, Numata A, et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant. 2007;39:523–7.
Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–76.
Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–97.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
Flinn IW, Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant. 2001;27:565–9.
Nademanee A, Forman SJ. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Semin Hematol. 2006;43:240–50.
Buckstein R, Imrie K, Spaner D, et al. Stem cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol. 1999;26(5 Suppl 14):115–22.
Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864–9.
Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777–83.
Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:921–3.
Cairoli R, Grillo G, Tedeschi A, D’Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica. 2004;89:361–3.
Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin’s lymphoma treated with VEPA or VEPA-M. J Clin Oncol. 1988;6:128–41.
Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23:87–9.
Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105:4143–5.
Kato K, Kanda Y, Eto T, et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2007;13:90–9.
Alousi AM, Saliba RM, Okoroji GJ, et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008;142:786–92.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Miyamoto, T. (2013). Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_94
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_94
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)